JP2004521871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004521871A5 JP2004521871A5 JP2002544432A JP2002544432A JP2004521871A5 JP 2004521871 A5 JP2004521871 A5 JP 2004521871A5 JP 2002544432 A JP2002544432 A JP 2002544432A JP 2002544432 A JP2002544432 A JP 2002544432A JP 2004521871 A5 JP2004521871 A5 JP 2004521871A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- alkyl
- optionally substituted
- formula
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 48
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 239000001257 hydrogen Substances 0.000 claims description 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical group 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 11
- -1 cyano, hydroxy Chemical group 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 108010060261 Adenosine A3 receptor Proteins 0.000 claims description 6
- 102000008161 Adenosine A3 receptor Human genes 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 6
- 125000005842 heteroatoms Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 6
- 239000001301 oxygen Chemical group 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 229910052717 sulfur Chemical group 0.000 claims description 6
- 239000011593 sulfur Chemical group 0.000 claims description 6
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 6
- 108010085273 Adenosine A2B receptor Proteins 0.000 claims description 5
- 102000007470 Adenosine A2B receptor Human genes 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 230000002757 inflammatory Effects 0.000 claims description 3
- 230000001404 mediated Effects 0.000 claims description 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
- 230000001387 anti-histamine Effects 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agents Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 230000003182 bronchodilatating Effects 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 2
- 230000000414 obstructive Effects 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000004913 activation Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- 101710039825 ADORA2B Proteins 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 0 **N(*=*)c([s]c(N(*)*)n1)c1[Al] Chemical compound **N(*=*)c([s]c(N(*)*)n1)c1[Al] 0.000 description 1
- YNGFNKUXMJZNCR-UHFFFAOYSA-N 3-[5-(2-methylimidazol-1-yl)-2-(pyrazin-2-ylamino)-1,3-thiazol-4-yl]benzonitrile Chemical compound CC1=NC=CN1C1=C(C=2C=C(C=CC=2)C#N)N=C(NC=2N=CC=NC=2)S1 YNGFNKUXMJZNCR-UHFFFAOYSA-N 0.000 description 1
- 108010060263 Adenosine A1 receptor Proteins 0.000 description 1
- 102000028568 Adenosine A1 receptor Human genes 0.000 description 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 description 1
- 102000007471 Adenosine A2A receptor Human genes 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- LDZZHWZCXFPJQO-UHFFFAOYSA-N methanesulfonic acid;3-[5-(2-methylimidazol-1-yl)-2-(pyrazin-2-ylamino)-1,3-thiazol-4-yl]benzonitrile Chemical compound CS(O)(=O)=O.CC1=NC=CN1C1=C(C=2C=C(C=CC=2)C#N)N=C(NC=2N=CC=NC=2)S1 LDZZHWZCXFPJQO-UHFFFAOYSA-N 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N n-pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Description
【特許請求の範囲】
【請求項1】 式I:
【化1】
[式中、
Arは、1価のC6−C15芳香族性の基であり;
R1は、水素か、ハロゲン、シアノ、ヒドロキシ、C1−C8−アルキル、C1−C8−ハロアルキル、C1−C8−アルコキシ、C1−C8−アルコキシ−C1−C8−アルキル、またはアシルオキシから選択される、1もしくはそれ以上の置換基によって、任意に置換されていることもあるフェニルか、またはC 1 −C 8 −アルキル、ヒドロキシ、C 1 −C 8 −アルコキシ、またはC 1 −C 8 −アルコキシ−C 1 −C 8 −アルコキシから選択される、1もしくはそれ以上の置換基によって、任意に置換されていることもある1価の5員環もしくは6員環の複素環であり;
R2は、水素、C1−C8−アルキル、アシル、または−CON(R3)R4であり、ただし、R1が水素のとき、R2がC1−C8−アルキル、アシル、または−CON(R3)R4であり;
R3とR4は、それぞれ独立に、水素またはC1−C8−アルキルであるか、またはそれらが結合している窒素原子と共に5員環もしくは6員環の複素環を表し;そして
Z1、Z2、Z3、およびZ4は、それぞれ独立に、N、またはCR5{式中、R5は、水素、C1−C8−アルキル、またはC1−C8−アルコキシである}であり、少なくともこれらのうちの1つがCR5である]の遊離形もしくは塩形である化合物。
【請求項2】 式中、Arは、ハロゲン、シアノ、C1−C8−アルキル、またはC1−C8−ハロアルキルから選択される、1もしくはそれ以上の置換基によって、任意に置換されていることもあるフェニルである、請求項1に記載の化合物。
【請求項3】 式中、Arは、示されているチアゾール環のメタ位もしくはパラ位で、ハロゲン、シアノ、またはC1−C8−アルキルによって、任意に置換されていることもあるフェニルである、請求項1に記載の化合物。
【請求項4】 式中、R1は、水素か、シアノもしくはC1−C4−アルコキシによって任意に置換されていることもあるフェニルか、またはC 1 −C 8 −アルキル、C 1 −C 8 −アルコキシ、またはC 1 −C 8 −アルコキシ−C 1 −C 8 −アルコキシから選択される、1もしくはそれ以上の置換基によって、任意に置換されていることもある1価の6員環のN−複素環である、請求項1、2、または3に記載の化合物。
【請求項5】 式中、R2は、水素、C1−C4−アルキルカルボニル、C3−C6−シクロアルキルカルボニル、フェニルカルボニル{式中、フェニル基は、C1−C8−アルコキシによって任意に置換されていることもある}、または複素環カルボニル{式中、複素環が5員環もしくは6員環であって、そして窒素、酸素、および硫黄から選択される1個の環複素原子を有する}である、請求項1から4の何れか1つに記載の化合物。
【請求項6】 式中、Arは、ハロゲンまたはシアノによって任意に置換されていることもあるフェニルであり;
R1は、水素か、シアノもしくはC1−C4−アルコキシによって任意に置換されていることもあるフェニルか、またはC 1 −C 8 −アルキル、C 1 −C 8 −アルコキシ、またはC 1 −C 8 −アルコキシ−C 1 −C 8 −アルコキシから選択される、1もしくはそれ以上の置換基によって、任意に置換されていることもある1価の6員環のN−複素環であり;
R2は、水素、C1−C4−アルキルカルボニル、C3−C6−シクロアルキルカルボニル、フェニルカルボニル{式中、フェニル基は、C1−C4−アルコキシによって任意に置換されていることもある}、または複素環カルボニル{式中、複素環は、5員環もしくは6員環であって、そして窒素、酸素、および硫黄から選択される、1もしくは2個の環複素原子を有する}であり;そして
Z1とZ3はそれぞれNを表し、かつZ2とZ4はそれぞれCHを表すか、またはZ1はCR5{式中、R5は、水素、またはC1−C4−アルキルである}を表し、Z2はNを表し、かつZ3とZ4はそれぞれCHを表す、請求項1に記載の化合物。
【請求項7】 式中、Arは、示されたチアゾール環のメタ位もしくはパラ位で、ハロゲンもしくはシアノによって任意に置換されていることもあるフェニルであり;
R1は、C 1 −C 8 −アルキル、C 1 −C 8 −アルコキシ、またはC 1 −C 8 −アルコキシ−C 1 −C 8 −アルコキシから選択される、1もしくはそれ以上の置換基によって、任意に置換されていることもある1価の6員環のN−複素環であり;
R2は、水素であり;そして
Z1とZ3はそれぞれNを表し、かつZ2とZ4はそれぞれCHを表すか、またはZ1はCR5{式中、R5は、水素、またはC1−C4−アルキルである}を表し、Z2はNを表し、かつZ3とZ4はそれぞれCHを表す、請求項1に記載の化合物。
【請求項8】 式中、Arは、示されたチアゾール環のメタ位もしくはパラ位で、ハロゲンまたはシアノによって置換されているフェニルであり;
R1は、水素であり;
R2は、フェニルカルボニル{式中、フェニルは、C1−C4−アルコキシによって任意に置換されていることもある}、または複素環カルボニル{式中、複素環は5員環もしくは6員環であって、そして酸素および硫黄から選択される、1個の環複素原子を有する}であり;そして
Z1とZ3はそれぞれNを表し、かつZ2とZ4はそれぞれCHを表すか、またはZ1はCR5{式中、R5は、水素、またはC1−C4−アルキルである}を表し、Z2はNを表し、かつZ3とZ4はそれぞれCHを表す、請求項1に記載の化合物。
【請求項9】 式 XI:
【化2】
[式中、Ra、Rb、R1、R2、Z1、Z2、Z3、およびZ4は、下記の表:
【表1】
【表2】
【表3】
【表4】
に示されている通りである]の遊離形もしくは塩形である化合物。
【請求項10】 抗炎症剤、気管支拡張剤、または抗ヒスタミン薬と組み合わせた、請求項1から9の何れかに記載の化合物であって、本化合物と該薬剤が、同一もしくは異なる医薬組成物中に存在する化合物。
【請求項11】 請求項1から9の何れかに記載の化合物を活性成分とする、アデノシンA2b受容体活性化阻害剤。
【請求項12】 請求項1から9の何れかに記載の化合物を活性成分とする、アデノシンA3受容体活性化阻害剤。
【請求項13】 任意に薬学的に許容される希釈剤もしくは担体と共に、活性成分として請求項1から10の何れかに記載の化合物を含む、炎症性またはアレルギー性状態の処置用医薬組成物。
【請求項14】 任意に薬学的に許容される希釈剤もしくは担体と共に、活性成分として請求項1から10の何れかに記載の化合物を含む、炎症性もしくは閉塞性気道疾患の処置用医薬組成物。
【請求項15】 請求項1記載の式Iの遊離形もしくは塩形である化合物を製造する方法であって、
(i)(A)式中、R1が、任意に置換されていることもあるフェニル、または5員環もしくは6員環の複素環である、式Iの化合物を製造するために、式 II:
【化3】
[式中、Ar、Z1、Z2、Z3、およびZ4は、請求項1で定義した通りであり、そしてXは、ハロゲンである]の塩形である化合物を、式 III:
【化4】
[式中、R1は、ハロゲン、シアノ、ヒドロキシ、C1−C8−アルキル、C1−C8−ハロアルキル、C1−C8−アルコキシ、C1−C8−アルコキシ−C1−C8−アルキル、およびアシルオキシから選択される、1もしくはそれ以上の置換基によって、任意に置換されていることもあるフェニルであるか、またはR1は、C 1 −C 8 −アルキル、ヒドロキシ、C 1 −C 8 −アルコキシ、またはC 1 −C 8 −アルコキシ−C 1 −C 8 −アルコキシから選択される、1もしくはそれ以上の置換基によって、任意に置換されていることもある1価の5員環もしくは6員環の複素環であり;そして
R2は、H、またはC1−C8−アルキルである]の化合物と反応させ;
(B)式中、R1が、任意に置換されていることもあるフェニル、または5員環もしくは6員環の複素環である、式Iの化合物を製造するために、式 IV:
【化5】
[式中、Ar、R1、R2、およびXは、方法(A)で定義した通りである]の化合物を、式V:
【化6】
[式中、Z1、Z2、Z3、およびZ4は、方法(A)で定義した通りである]の化合物と反応させ;または
(C)式中、R2は、アシル、または−CON(R3)R4である、式Iの化合物を製造するために、式 VI:
【化7】
[式中、Ar、R1、Z1、Z2、Z3、およびZ4は、請求項1で定義した通りである]の化合物を、それぞれカルボン酸のアシル化誘導体と、または式:Cl−CON(R3)R4{式中、R3とR4は、請求項1で定義した通りである}と、反応させ;そして
(ii)得られた式Iの遊離形もしくは塩形である化合物を回収する;
ことを含む方法。
[Claims]
1. Formula I:
[Chemical 1]
[Where
Ar is monovalent C6-C15An aromatic group;
R1Is hydrogen, halogen, cyano, hydroxy, C1-C8-Alkyl, C1-C8-Haloalkyl, C1-C8-Alkoxy, C1-C8-Alkoxy-C1-C8-Optionally substituted by one or more substituents selected from alkyl or acyloxySometimesPhenyl orC 1 -C 8 -Alkyl, hydroxy, C 1 -C 8 -Alkoxy or C 1 -C 8 -Alkoxy-C 1 -C 8 A monovalent which may be optionally substituted by one or more substituents selected from alkoxy5 or 6 membersRingIs a heterocycle;
R2Is hydrogen, C1-C8-Alkyl, acyl, or -CON (R3) R4However, R1R is hydrogen2Is C1-C8-Alkyl, acyl, or -CON (R3) R4Is;
R3And R4Each independently represents hydrogen or C1-C8-Represents a 5- or 6-membered heterocycle, which is alkyl or together with the nitrogen atom to which they are attached; and
Z1, Z2, Z3, And Z4Are independently N or CR5{Where R is5Is hydrogen, C1-C8-Alkyl or C1-C8-Alkoxy}, at least one of which is CR5Is a free form or a salt form of
2. In the formula, Ar is halogen, cyano, C1-C8-Alkyl or C1-C8-Optionally substituted by one or more substituents selected from haloalkylSometimes2. A compound according to claim 1 which is phenyl.
3. In the formula, Ar is a meta-position or a para-position of the indicated thiazole ring, halogen, cyano, or C1-C8Optionally substituted by alkylSometimes2. A compound according to claim 1 which is phenyl.
4. In the formula, R1Is hydrogen, cyano or C1-C4Optionally substituted by alkoxySometimesPhenyl orC 1 -C 8 -Alkyl, C 1 -C 8 -Alkoxy or C 1 -C 8 -Alkoxy-C 1 -C 8 -Optionally substituted by one or more substituents selected from alkoxyThe compound according to claim 1, 2, or 3, which is a monovalent 6-membered N-heterocycle.
5. In the formula, R2Is hydrogen, C1-C4-Alkylcarbonyl, C3-C6-Cycloalkylcarbonyl, phenylcarbonyl {wherein the phenyl group is C1-C8Optionally substituted by alkoxySometimesOr a heterocyclic carbonyl {wherein the heterocycle is a 5- or 6-membered ring and has one ring heteroatom selected from nitrogen, oxygen, and sulfur}. 5. The compound according to any one of 4 to 4.
6. In the formula, Ar is optionally substituted by halogen or cyano.SometimesPhenyl;
R1Is hydrogen, cyano or C1-C4Optionally substituted by alkoxySometimesPhenyl orC 1 -C 8 -Alkyl, C 1 -C 8 -Alkoxy or C 1 -C 8 -Alkoxy-C 1 -C 8 -Optionally substituted by one or more substituents selected from alkoxyA monovalent 6-membered N-heterocycle;
R2Is hydrogen, C1-C4-Alkylcarbonyl, C3-C6-Cycloalkylcarbonyl, phenylcarbonyl {wherein the phenyl group is C1-C4Optionally substituted by alkoxySometimes}, Or heterocyclic carbonyl {wherein the heterocycle is a 5- or 6-membered ring and has 1 or 2 ring heteroatoms selected from nitrogen, oxygen, and sulfur} And
Z1And Z3Each represents N and Z2And Z4Each represents CH or Z1Is CR5{Where R is5Is hydrogen or C1-C4-Alkyl} and Z2Represents N and Z3And Z4The compound according to claim 1, wherein each represents CH.
7. Ar is optionally substituted with halogen or cyano at the meta or para position of the indicated thiazole ring.SometimesPhenyl;
R1IsC 1 -C 8 -Alkyl, C 1 -C 8 -Alkoxy or C 1 -C 8 -Alkoxy-C 1 -C 8 -Optionally substituted by one or more substituents selected from alkoxyA monovalent 6-membered N-heterocycle;
R2Is hydrogen; and
Z1And Z3Each represents N and Z2And Z4Each represents CH or Z1Is CR5{Where R is5Is hydrogen or C1-C4-Alkyl} and Z2Represents N and Z3And Z4The compound according to claim 1, wherein each represents CH.
8. Ar is phenyl substituted at the meta-position or para-position of the indicated thiazole ring by halogen or cyano;
R1Is hydrogen;
R2Is phenylcarbonyl {wherein phenyl is C1-C4Optionally substituted by alkoxySometimesOr a heterocyclic carbonyl {wherein the heterocycle is a 5- or 6-membered ring and has one ring heteroatom selected from oxygen and sulfur}; and
Z1And Z3Each represents N and Z2And Z4Each represents CH or Z1Is CR5{Where R is5Is hydrogen or C1-C4-Alkyl} and Z2Represents N and Z3And Z4The compound according to claim 1, wherein each represents CH.
9. Formula XI:
[Chemical 2]
[Wherein Ra, Rb, R1, R2, Z1, Z2, Z3, And Z4The following table:
[Table 1]
[Table 2]
[Table 3]
[Table 4]
A compound in a free form or a salt form].
10. A compound according to any one of claims 1 to 9 in combination with an anti-inflammatory agent, bronchodilator or antihistamine, wherein the compound and the agent are the same or different. A compound present in it.
11. Claims An adenosine A2b receptor activation inhibitor comprising the compound according to any one of claims 1 to 9 as an active ingredient.
[Claim 12] An adenosine A3 receptor activation inhibitor comprising the compound according to any one of claims 1 to 9 as an active ingredient.
13. An active ingredient according to any one of claims 1 to 10, optionally together with a pharmaceutically acceptable diluent or carrier.CrabContaining the described compounds,For the treatment of inflammatory or allergic conditionsPharmaceutical composition.
14. An active ingredient according to any one of claims 1 to 10, optionally together with a pharmaceutically acceptable diluent or carrier.CrabInflammatory or obstructive airway diseases comprising the compounds describedPharmaceutical composition for treatment of.
15. Claims Claim 1A process for preparing a compound of formula I in free or salt form, comprising
(i) In formula (A), R1Is optionally substitutedSometimesTo prepare a compound of formula I which is phenyl or a 5- or 6-membered heterocycle, formula II:
[Chemical Formula 3]
[Wherein Ar, Z1, Z2, Z3, And Z4Is as defined in claim 1 and X is a halogen].
[Formula 4]
[Wherein R1Is halogen, cyano, hydroxy, C1-C8-Alkyl, C1-C8-Haloalkyl, C1-C8-Alkoxy, C1-C8-Alkoxy-C1-C8-Optionally substituted by one or more substituents selected from alkyl and acyloxySometimesPhenyl or R1IsC 1 -C 8 -Alkyl, hydroxy, C 1 -C 8 -Alkoxy or C 1 -C 8 -Alkoxy-C 1 -C 8 -Optionally substituted by one or more substituents selected from alkoxyA monovalent 5- or 6-membered heterocyclic ring; and
R2Is H or C1-C8Reaction with a compound of -alkyl];
(B) where R1Is optionally substitutedSometimesTo prepare a compound of formula I which is phenyl or a 5- or 6-membered heterocycle, formula IV:
[Chemical formula 5]
[Wherein Ar, R1, R2, And X are as defined in method (A)].
[Chemical 6]
[Where Z1, Z2, Z3, And Z4Is as defined in method (A)]; or
(C) where R2Is acyl or -CON (R3) R4To produce a compound of formula I, formula VI:
[Chemical 7]
[Wherein Ar, R1, Z1, Z2, Z3, And Z4Are as defined in claim 1], each with an acylated derivative of a carboxylic acid, or a compound of the formula Cl-CON (R3) R4{Where R is3And R4Is as defined in claim 1} and reacts; and
(ii) recovering the resulting compound in free form or salt form of formula I;
A method involving that.
式Iの化合物およびその薬学的に許容される塩は、医薬として有用である。特に、これらは、アデノシンA2b受容体の活性化の阻害を示す。すなわちこれらはA2b受容体アンタゴニストとして作用する。さらに、一般的に、これらはA2b受容体の活性化を、アデノシンA1受容体およびアデノシンA2a受容体に対して、選択的に阻害する。これらの阻害の性質は、下記の試験方法で示され得る。 The compounds of formula I and their pharmaceutically acceptable salts are useful as pharmaceuticals. In particular, they exhibit inhibition of activation of the adenosine A2b receptor. That is, they act as A2b receptor antagonists. Furthermore, in general, activation of A2b receptor, for adenosine A1 receptors and adenosine A2a receptor, selectively inhibit. The nature of these inhibitions can be demonstrated by the following test methods.
一般的に、式Iの化合物の遊離形もしくは薬学的に許容される塩形はまた、アデノシンA3受容体活性化の阻害を示す。このことは、WO99/64418に記載されたアデノシンA3受容体アッセイで示され得る。例えば実施例7、27、30、31、34、35、および38の化合物は、このアッセイ中で、それぞれ24nM、16nM、22nM、11.5nM、11nM、10nM、および4nMのKI値を有する。 Generally, in free form or pharmaceutically acceptable salt forms of the compounds of formula I also exhibit inhibition of adenosine A3 receptor activation. This can be shown in the adenosine A3 receptor assay described in WO 99/64418. For example, the compounds of Examples 7,27,30,31,34,35 and 38, in this assay, each with 24nM, 16nM, 22nM, 11.5nM, 11nM, 10nM, and the K I values of 4 nM.
アデノシンA2b受容体活性化のこれらの阻害、および一般的なアデノシンA3受容体活性化のこれらの阻害に関して、式Iの化合物の遊離形もしくは薬学的に許容される塩形(以降本発明と言う)は、アデノシンA2b受容体もしくはアデノシンA3受容体の活性化が介在する状態、特に炎症性もしくはアレルギー性状態の処置に有用である。本発明に従う処置は、症候的であっても予防的であってもよい。 Inhibition of adenosine A2b receptor activation, and for these inhibitory general adenosine A3 receptor activation, (referred to hereinafter present invention) in free form or in pharmaceutically acceptable salt form of a compound of formula I Is useful for the treatment of conditions mediated by activation of adenosine A2b receptor or adenosine A3 receptor, particularly inflammatory or allergic conditions. Treatment according to the present invention may be symptomatic or prophylactic.
実施例38:(3−[5−(2−メチル−イミダゾール−1−イル)−2−(ピラジン−2−イルアミノ)−チアゾール−4−イル]−ベンゾニトリル)メタンスルホン酸塩
(3−[5−(2−メチル−イミダゾール−1−イル)−2−(ピラジン−2−イルアミノ)−チアゾール−4−イル]−ベンゾニトリル(1g, 2.78mmol)を、沸騰ペンタノール(25ml)に懸濁し、熱ろ過し、透明な溶液を得る。メタンスルホン酸(0.2ml, 3.06mmol)を加え、混合物を室温まで冷却し、固体を沈殿させる。ジエチルエーテル(25ml)を攪拌しながら加え、固体をろ過して除き、ジエチルエーテルで洗浄し、次にジエチルエーテル(25ml)でトリチュレートする。得られた固体をろ過し、真空下で乾燥し、沸騰アセトン(20ml)に懸濁する。水(2ml)、次にアセトン(5ml)を加え、得られた溶液を4℃まで冷却する。得られた固体をろ過し、アセトンで洗浄し、真空下、80℃でP2O5で乾燥し、表題化合物を得る。
m.p. 282℃;
Example 38 : (3- [5- (2-Methyl-imidazol-1-yl) -2- (pyrazin-2-ylamino) -thiazol-4-yl] -benzonitrile) methanesulfonate
(3- [5- (2-Methyl-imidazol-1-yl) -2- (pyrazin-2-ylamino) -thiazol-4-yl] -benzonitrile (1 g, 2.78 mmol) was added to boiling pentanol ( 25 mL), hot filtered to obtain a clear solution, methanesulfonic acid (0.2 mL, 3.06 mmol) is added, the mixture is cooled to room temperature and a solid is precipitated. The solid is filtered off, washed with diethyl ether and then triturated with diethyl ether (25 ml) The resulting solid is filtered, dried under vacuum and suspended in boiling acetone (20 ml). Water (2 ml) and then acetone (5 ml) are added and the resulting solution is cooled to 4 ° C. The resulting solid is filtered, washed with acetone and P 2 O 5 at 80 ° C. under vacuum. To give the title compound.
m.p. 282 ° C;
Claims (14)
Arは、1価のC6−C15芳香族性の基であり;
R1は、水素か、ハロゲン、シアノ、ヒドロキシ、C1−C8−アルキル、C1−C8−ハロアルキル、C1−C8−アルコキシ、C1−C8−アルコキシ−C1−C8−アルキル、またはアシルオキシから選択される、1もしくはそれ以上の置換基によって、任意に置換されているフェニルか、または5員環もしくは6員環の1価の複素環であり;
R2は、水素、C1−C8−アルキル、アシル、または−CON(R3)R4であり、そしてR2がC1−C8−アルキル、アシル、または−CON(R3)R4であれば、R1は水素であり;
R3とR4は、それぞれ独立に、水素またはC1−C8−アルキルであるか、またはそれらが結合している窒素原子と共に5員環もしくは6員環の複素環を表し;そして
Z1、Z2、Z3、およびZ4は、それぞれ独立に、N、またはCR5{式中、R5は、水素、C1−C8−アルキル、またはC1−C8−アルコキシである}であり、少なくともこれらのうちの1つがCR5である]の遊離形もしくは塩形である化合物。Formula I:
Ar is a monovalent C 6 -C 15 aromatic group;
R 1 is hydrogen, halogen, cyano, hydroxy, C 1 -C 8 -alkyl, C 1 -C 8 -haloalkyl, C 1 -C 8 -alkoxy, C 1 -C 8 -alkoxy-C 1 -C 8 -Phenyl optionally substituted by one or more substituents selected from alkyl, or acyloxy, or a monovalent heterocyclic ring of 5 or 6 members;
R 2 is hydrogen, C 1 -C 8 -alkyl, acyl, or —CON (R 3 ) R 4 , and R 2 is C 1 -C 8 -alkyl, acyl, or —CON (R 3 ) R If 4 , R 1 is hydrogen;
R 3 and R 4 are each independently hydrogen or C 1 -C 8 -alkyl or represent a 5- or 6-membered heterocyclic ring with the nitrogen atom to which they are attached; and Z 1 , Z 2 , Z 3 , and Z 4 are each independently N, or CR 5 , wherein R 5 is hydrogen, C 1 -C 8 -alkyl, or C 1 -C 8 -alkoxy} And at least one of these is CR 5 ].
R1は、水素か、シアノもしくはC1−C4−アルコキシによって任意に置換されているフェニルか、または1価の6員環のN−複素環であり;
R2は、水素、C1−C4−アルキルカルボニル、C3−C6−シクロアルキルカルボニル、フェニルカルボニル{式中、フェニル基は、C1−C4−アルコキシによって任意に置換されている}、または複素環カルボニル{式中、複素環は、5員環もしくは6員環であって、そして窒素、酸素、および硫黄から選択される、1もしくは2個の環複素原子を有する}であり;そして
Z1とZ3はそれぞれNを表し、かつZ2とZ4はそれぞれCHを表すか、またはZ1はCR5{式中、R5は、水素、またはC1−C4−アルキルである}を表し、Z2はNを表し、かつZ3とZ4はそれぞれCHを表す、請求項1に記載の化合物。Wherein Ar is phenyl optionally substituted with halogen or cyano;
R 1 is hydrogen, phenyl optionally substituted by cyano or C 1 -C 4 -alkoxy, or a monovalent 6-membered N-heterocycle;
R 2 is hydrogen, C 1 -C 4 -alkylcarbonyl, C 3 -C 6 -cycloalkylcarbonyl, phenylcarbonyl {wherein the phenyl group is optionally substituted by C 1 -C 4 -alkoxy} Or a heterocyclic carbonyl {wherein the heterocycle is a 5- or 6-membered ring and has 1 or 2 ring heteroatoms selected from nitrogen, oxygen and sulfur}; And Z 1 and Z 3 each represent N, and Z 2 and Z 4 each represent CH, or Z 1 represents CR 5 wherein R 5 is hydrogen or C 1 -C 4 -alkyl. The compound according to claim 1, wherein Z 2 represents N, and Z 3 and Z 4 each represent CH.
R1は、1価の6員環のN−複素環であり;
R2は、水素であり;そして
Z1とZ3はそれぞれNを表し、かつZ2とZ4はそれぞれCHを表すか、またはZ1はCR5{式中、R5は、水素、またはC1−C4−アルキルである}を表し、Z2はNを表し、かつZ3とZ4はそれぞれCHを表す、請求項1に記載の化合物。Wherein Ar is phenyl optionally substituted with halogen or cyano at the meta or para position of the indicated thiazole ring;
R 1 is a monovalent 6-membered N-heterocycle;
R 2 is hydrogen; and Z 1 and Z 3 each represent N, and Z 2 and Z 4 each represent CH, or Z 1 represents CR 5 wherein R 5 is hydrogen, or The compound according to claim 1, which represents C 1 -C 4 -alkyl}, Z 2 represents N, and Z 3 and Z 4 each represent CH.
R1は、水素であり;
R2は、フェニルカルボニル{式中、フェニルは、C1−C4−アルコキシによって任意に置換されている}、または複素環カルボニル{式中、複素環は5員環もしくは6員環であって、そして酸素および硫黄から選択される、1個の環複素原子を有する}であり;そして
Z1とZ3はそれぞれNを表し、かつZ2とZ4はそれぞれCHを表すか、またはZ1はCR5{式中、R5は、水素、またはC1−C4−アルキルである}を表し、Z2はNを表し、かつZ3とZ4はそれぞれCHを表す、請求項1に記載の化合物。Wherein Ar is phenyl substituted at the meta or para position of the indicated thiazole ring by halogen or cyano;
R 1 is hydrogen;
R 2 is phenylcarbonyl {wherein phenyl is optionally substituted by C 1 -C 4 -alkoxy}, or heterocyclic carbonyl {wherein the heterocycle is a 5- or 6-membered ring; And having one ring heteroatom selected from oxygen and sulfur; and Z 1 and Z 3 each represent N and Z 2 and Z 4 each represent CH or Z 1 2 represents CR 5 , wherein R 5 is hydrogen or C 1 -C 4 -alkyl, Z 2 represents N, and Z 3 and Z 4 each represent CH. The described compound.
(i)(A)式中、R1が、任意に置換されているフェニル、または5員環もしくは6員環の複素環である、式Iの化合物を製造するために、式 II:
R2は、H、またはC1−C8−アルキルである]の化合物と反応させ;
(B)式中、R1が、任意に置換されているフェニル、または5員環もしくは6員環の複素環である、式Iの化合物を製造するために、式 IV:
(C)式中、R2は、アシル、または−CON(R3)R4である、式Iの化合物を製造するために、式 VI:
(ii)得られた式Iの遊離形もしくは塩形である化合物を回収する;
ことを含む方法。A process for preparing a compound of formula I in free or salt form, comprising
(i) To prepare compounds of formula I wherein R 1 is optionally substituted phenyl, or a 5- or 6-membered heterocycle, Formula II:
(B) To prepare compounds of formula I, wherein R 1 is optionally substituted phenyl, or a 5- or 6-membered heterocycle, Formula IV:
(C) To prepare compounds of formula I, wherein R 2 is acyl, or —CON (R 3 ) R 4
(ii) recovering the resulting compound in free form or salt form of formula I;
A method involving that.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0028383.8A GB0028383D0 (en) | 2000-11-21 | 2000-11-21 | Organic compounds |
PCT/EP2001/013378 WO2002042298A1 (en) | 2000-11-21 | 2001-11-19 | Aminothiazoles and their use as adenosine receptor antagonists |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004521871A JP2004521871A (en) | 2004-07-22 |
JP2004521871A5 true JP2004521871A5 (en) | 2007-06-14 |
JP3973556B2 JP3973556B2 (en) | 2007-09-12 |
Family
ID=9903594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002544432A Expired - Fee Related JP3973556B2 (en) | 2000-11-21 | 2001-11-19 | Aminothiazole and its use as an adenosine receptor antagonist |
Country Status (26)
Country | Link |
---|---|
US (1) | US7109202B2 (en) |
EP (1) | EP1339711B1 (en) |
JP (1) | JP3973556B2 (en) |
KR (1) | KR20040007412A (en) |
CN (1) | CN1244580C (en) |
AR (1) | AR035371A1 (en) |
AT (1) | ATE300536T1 (en) |
AU (1) | AU2002237221A1 (en) |
BR (1) | BR0115478A (en) |
CA (1) | CA2429442A1 (en) |
CZ (1) | CZ20031393A3 (en) |
DE (1) | DE60112322T2 (en) |
EC (1) | ECSP034611A (en) |
ES (1) | ES2246346T3 (en) |
GB (1) | GB0028383D0 (en) |
HU (1) | HUP0302079A2 (en) |
IL (1) | IL155712A0 (en) |
MX (1) | MXPA03004439A (en) |
NO (1) | NO20032277L (en) |
NZ (1) | NZ525875A (en) |
PE (1) | PE20020580A1 (en) |
PL (1) | PL361842A1 (en) |
RU (1) | RU2003117476A (en) |
SK (1) | SK6032003A3 (en) |
WO (1) | WO2002042298A1 (en) |
ZA (1) | ZA200303721B (en) |
Families Citing this family (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020115635A1 (en) * | 2001-02-21 | 2002-08-22 | Pnina Fishman | Modulation of GSK-3beta activity and its different uses |
AU2002349705A1 (en) * | 2001-12-03 | 2003-06-17 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
SI1466912T1 (en) * | 2002-01-18 | 2013-08-30 | Astellas Pharma Inc. | 2-acylaminothiazole derivative or salt thereof |
AR044519A1 (en) | 2003-05-02 | 2005-09-14 | Novartis Ag | DERIVATIVES OF PIRIDIN-TIAZOL AMINA AND PIRIMIDIN-TIAZOL AMINA |
TW200524887A (en) * | 2003-10-27 | 2005-08-01 | Lundbeck & Co As H | N-thiazol-2-yl-benzamide derivatives |
EA013249B1 (en) * | 2003-12-26 | 2010-04-30 | Киова Хакко Кирин Ко., Лтд. | Thiazole derivative |
GB0401336D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
PE20060272A1 (en) * | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2R, 3R, 4S, 5R, 2'R, 3'R, 4'S, 5'S) -2.2 '- {TRANS-1,4-CYCLOHEXANODIYLBIS- [IMINO (2 - {[2- (1-METHYL- 1H-IMIDAZOL-4-IL) ETHYL] AMINO} -9H-PURIN-6,9-DIYL)]} BIS [5- (2-ETHYL-2H-TETRAZOLE-5-IL) TETRAHYDRO-3,4-FURANODIOL] AS AN A2A AGONIST |
GB0417910D0 (en) * | 2004-08-11 | 2004-09-15 | Novartis Ag | Organic compounds |
JP4942045B2 (en) * | 2004-09-22 | 2012-05-30 | ハー・ルンドベック・アクチエゼルスカベット | 2-acylaminothiazole derivatives |
WO2006032273A1 (en) * | 2004-09-22 | 2006-03-30 | H. Lundbeck A/S | 2-acylaminothiazole derivatives |
GT200500281A (en) | 2004-10-22 | 2006-04-24 | Novartis Ag | ORGANIC COMPOUNDS. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
US7674912B2 (en) | 2005-04-25 | 2010-03-09 | H. Lundbeck A/S | Pro-drugs of N-thiazol-2-yl-benzamide derivatives |
EA200702445A1 (en) * | 2005-05-09 | 2008-04-28 | Ачиллион Фармасьютикалз, Инк. | THIAZOLE COMPOUNDS AND METHODS OF THEIR APPLICATION |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
CA2610884A1 (en) * | 2005-06-09 | 2006-12-21 | Merck & Co., Inc. | Inhibitors of checkpoint kinases |
WO2006137527A1 (en) | 2005-06-23 | 2006-12-28 | Kyowa Hakko Kogyo Co., Ltd. | Thiazole derivative |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
ES2270715B1 (en) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | NEW DERIVATIVES OF PIRAZINA. |
SI1921077T1 (en) * | 2005-08-02 | 2017-11-30 | Kyowa Hakko Kirin Co., Ltd. | Agent for treating and/or preventing sleep disorder |
GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
EP1924553A1 (en) | 2005-08-08 | 2008-05-28 | Argenta Discovery Limited | Bicyclo[2.2.]hept-7-ylamine derivatives and their uses |
JP5341516B2 (en) | 2005-09-13 | 2013-11-13 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 2-aniline-4-aryl-substituted thiazole derivatives |
ES2274712B1 (en) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | NEW IMIDAZOPIRIDINE DERIVATIVES. |
AR058104A1 (en) | 2005-10-21 | 2008-01-23 | Novartis Ag | ORGANIC COMPOUNDS |
AU2006313491B2 (en) * | 2005-11-08 | 2011-01-06 | Astellas Pharma Inc. | Compositions and methods for treating thrombocytopenia |
GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
AU2007227021B2 (en) * | 2006-03-17 | 2012-12-20 | Gilead Sciences, Inc. | Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists |
US8217037B2 (en) * | 2006-04-07 | 2012-07-10 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers |
AR060607A1 (en) | 2006-04-21 | 2008-07-02 | Novartis Ag | PURINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION METHOD AND USES IN OBSTRUCTIVE OR INFLAMMATORY DISEASES OF RESPIRATORY ROADS. |
EP2452674B1 (en) * | 2006-08-08 | 2014-03-26 | Akarx, Inc. | Compositions and methods for increasing blood platelet levels in humans |
WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
AU2007315234A1 (en) | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
ATE493174T1 (en) | 2007-01-10 | 2011-01-15 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS CHANNEL-ACTIVATE PROTEASE INHIBITORS |
MX2009012077A (en) | 2007-05-07 | 2009-11-19 | Novartis Ag | Organic compounds. |
ES2424023T3 (en) | 2007-10-18 | 2013-09-26 | Janssen Pharmaceutica N.V. | 1,2,4-trisubstituted triazoles |
JO2784B1 (en) | 2007-10-18 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | 1,3,5-trisubstitued triazole derivative |
PT2444120T (en) | 2007-12-10 | 2018-01-03 | Novartis Ag | Spirocyclic amiloride analogues as enac blockers |
EP2327693B9 (en) | 2007-12-14 | 2012-10-24 | Pulmagen Therapeutics (Asthma) Limited | Indoles and their therapeutic use |
ES2442930T3 (en) | 2008-01-11 | 2014-02-14 | Novartis Ag | Pyrimidines as kinase inhibitors |
AU2009218861A1 (en) * | 2008-02-25 | 2009-09-03 | Merck Patent Gmbh | Glucokinase activators |
CN102066343B (en) | 2008-03-19 | 2013-12-04 | 詹森药业有限公司 | Trisubstituted 1, 2, 4 -triazoiies as nicotinic acetylcholine receptor modulators |
WO2009135944A1 (en) | 2008-05-09 | 2009-11-12 | Janssen Pharmaceutica Nv | Trisubstituted pyrazoles as acetylcholine receptor modulators |
MX2010013675A (en) | 2008-06-10 | 2011-02-15 | Novartis Ag | Pyrazine derivatives as epithelial sodium channel blockers. |
CN101747327B (en) * | 2008-12-02 | 2013-03-27 | 中国人民解放军军事医学科学院毒物药物研究所 | Aromatic amide thiazole derivative, preparation method and application thereof |
SI2391366T1 (en) | 2009-01-29 | 2013-01-31 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
EA201190119A1 (en) | 2009-02-17 | 2012-05-30 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | DERIVATIVES OF TRIAZOLOPIRIDINE AS MAR-KINASE INHIBITORS p38 |
GB0902648D0 (en) | 2009-02-17 | 2009-04-01 | Argenta Discovery Ltd | Pharmaceutical compounds and compositions |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
WO2011018454A1 (en) | 2009-08-12 | 2011-02-17 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
US20110166112A1 (en) * | 2009-08-14 | 2011-07-07 | Eisai, Inc. | Method for stimulating platelet production |
CA2771532C (en) | 2009-08-17 | 2021-03-23 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
IN2012DN01453A (en) | 2009-08-20 | 2015-06-05 | Novartis Ag | |
EP2490687A1 (en) | 2009-10-22 | 2012-08-29 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
GB201009731D0 (en) | 2010-06-10 | 2010-07-21 | Pulmagen Therapeutics Inflamma | Kinase inhibitors |
BR112012032766A2 (en) | 2010-06-30 | 2019-09-24 | Gilead Sciences Inc | use of a2b adenosine receptor antagonists for the treatment of pulmonary hypertension |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
WO2012107500A1 (en) | 2011-02-10 | 2012-08-16 | Novartis Ag | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
CA2828219A1 (en) | 2011-02-25 | 2012-08-30 | Irm Llc | Pyrazolo [1,5-a] pyridines as trk inhibitors |
WO2012125400A1 (en) * | 2011-03-14 | 2012-09-20 | Acorn Biomedical, Inc. | Compositions and methods using adenosine a3 receptor antagonists for the treatment of inflammatory eye diseases |
AR085942A1 (en) | 2011-04-07 | 2013-11-06 | Gilead Sciences Inc | USE OF AADENOSINE RECEPTOR TO TREAT CARDIAC INSUFFICIENCY AND ARRITMIA IN POST-INFAR PATIENTS OF MYOCARDIUM |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
ES2691650T3 (en) | 2011-09-15 | 2018-11-28 | Novartis Ag | 3- (quinolin-6-yl-thio) - [1,2,4] -triazolo- [4,3-a] -pyridines 6-substituted as inhibitors of tyrosine kinase c-Met |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
US9034879B2 (en) | 2011-09-16 | 2015-05-19 | Novartis Ag | Heterocyclic compounds for the treatment of CF |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
ES2882807T3 (en) | 2011-09-16 | 2021-12-02 | Novartis Ag | N-substituted heterocyclyl carboxamides |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
DE102011083283A1 (en) * | 2011-09-23 | 2013-03-28 | Beiersdorf Ag | Heteroalkylamidothiazoles, their cosmetic or dermatological use and cosmetic or dermatological preparations containing such Heteroalkylamidothiazolen |
EP2793893A4 (en) | 2011-11-23 | 2015-07-08 | Intellikine Llc | Enhanced treatment regimens using mtor inhibitors |
CN103974953B (en) | 2011-12-09 | 2016-06-29 | 奇斯药制品公司 | Inhibitors of kinases |
US9458154B2 (en) | 2011-12-09 | 2016-10-04 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
KR101994381B1 (en) | 2011-12-09 | 2019-06-28 | 키에시 파르마슈티시 엣스. 피. 에이. | Kinase inhibitors |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
EP2834246B1 (en) | 2012-04-03 | 2021-07-28 | Novartis AG | Combination products with tyrosine kinase inhibitors and their use |
CN102964343A (en) * | 2012-12-10 | 2013-03-13 | 湖南大学 | N-acyl-4-tertiary butyl-5-(1, 2, 4-triazole-1-yl) thiazole-2-amine and preparation method and application thereof |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
BR112015029970A2 (en) | 2013-06-06 | 2017-07-25 | Chiesi Farm Spa | kinase inhibitors |
US9453002B2 (en) | 2013-08-16 | 2016-09-27 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
EA201692140A1 (en) | 2014-04-24 | 2017-04-28 | Новартис Аг | DERIVATIVES OF AMINOPYRIDINE AS PHOSPHATIDYLINOSYTOL 3-KINASE INHIBITORS |
CA2945212A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
ES2667424T3 (en) | 2014-04-24 | 2018-05-10 | Novartis Ag | Pyrazine derivatives as phosphatidyl-inositol-3-kinase inhibitors |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
CA2954862A1 (en) | 2014-07-31 | 2016-02-04 | Novartis Ag | Combination therapy |
CN105367564B (en) * | 2014-09-01 | 2018-03-23 | 湖南大学 | N [base of 4 phenyl 5 (base of 1,2,4 triazole 1) thiazole 2] acid amides and its preparation and application |
TW201720828A (en) | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | Therapeutic compounds and compositions, and methods of use thereof |
EP3394054B1 (en) * | 2015-12-21 | 2019-11-06 | Council of Scientific and Industrial Research | Novel 1,2,3 triazole-thiazole compounds, process for preparation and use thereof |
MA44131A (en) | 2015-12-23 | 2021-05-26 | Chiesi Farm Spa | DERIVATIVES OF 1- (3-TERT-BUTYL-2H-PYRAZOL-5-YL OR 5-TERT-BUTYL-ISOXAOL-3-YL) -3- (4 - ([1,2,4] TRIAZOLO [4,3 -A] PYRIDIN-6-YLOXY) -1,2,3,4-TETRAHYDRO-NAPHTHALENYL) UREA AND THEIR USE AS P38 MAPK INHIBITORS |
EP3394058B1 (en) | 2015-12-23 | 2020-10-14 | Chiesi Farmaceutici S.p.A. | N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors |
TW201730189A (en) | 2015-12-23 | 2017-09-01 | 吉斯藥品公司 | Kinase inhibitors |
CN109476638B (en) | 2016-05-05 | 2021-12-28 | 豪夫迈·罗氏有限公司 | Pyrazole derivatives, compositions and therapeutic uses thereof |
PE20190632A1 (en) | 2016-09-06 | 2019-04-26 | Hoffmann La Roche | COMPOUNDS 8- (AZETIDIN-1-IL) - [1,2,4] TRIAZOLO [1,5-A] PIRIDINYL, COMPOSITIONS AND METHODS OF USING THEMSELVES |
CR20190310A (en) | 2016-12-29 | 2019-08-21 | Hoffmann La Roche | Pyrazolopyrimidine compounds and methods of use thereof |
ES2676535B1 (en) * | 2017-01-20 | 2019-04-29 | Palobiofarma Sl | MODULATORS OF A3 ADENOSINE RECEIVERS |
WO2018166993A2 (en) | 2017-03-14 | 2018-09-20 | F. Hoffmann-La Roche Ag | Pyrazolochlorophenyl compounds, compositions and methods of use thereof |
SG11201909735YA (en) | 2017-05-22 | 2019-11-28 | Hoffmann La Roche | Therapeutic compounds and compositions, and methods of use thereof |
EP3630767A1 (en) | 2017-05-22 | 2020-04-08 | H. Hoffnabb-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
US10364245B2 (en) | 2017-06-07 | 2019-07-30 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
CN109293652B (en) * | 2017-07-24 | 2021-10-22 | 四川科伦博泰生物医药股份有限公司 | Substituted thiazole derivative and application thereof |
KR102007640B1 (en) * | 2017-11-29 | 2019-08-07 | 퓨쳐메디신 주식회사 | The pharmaceutical compositions for the prevention and treatment of retinal diseases or optic nerve diseases containing adenosine derivatives |
EP3740488A1 (en) | 2018-01-15 | 2020-11-25 | F. Hoffmann-La Roche AG | Pyrazolopyrimidine compounds as jak inhibitors |
US20200383960A1 (en) | 2019-06-10 | 2020-12-10 | Novartis Ag | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis |
JP2022537964A (en) | 2019-06-18 | 2022-08-31 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Pyrazolopyrimidine sulfone inhibitors of JAK kinases and uses thereof |
EP3986899A1 (en) | 2019-06-18 | 2022-04-27 | F. Hoffmann-La Roche AG | Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof |
US20200399274A1 (en) | 2019-06-18 | 2020-12-24 | Genentech, Inc. | Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof |
JP2022547427A (en) | 2019-08-28 | 2022-11-14 | ノバルティス アーゲー | Substituted 1,3-phenylheteroaryl derivatives and their use in treating disease |
TW202140550A (en) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | Methods of treating an inflammatory or obstructive airway disease using anti-tslp antibody |
WO2023139132A1 (en) * | 2022-01-19 | 2023-07-27 | Leadxpro Ag | Functionalized aminothiazoles |
GB2615307A (en) * | 2022-01-28 | 2023-08-09 | Adorx Therapeutics Ltd | Antagonist compounds |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8917849D0 (en) * | 1989-08-04 | 1989-09-20 | Shell Int Research | Thiazole derivatives,their preparation and their use as fungicides |
JPH04118648A (en) | 1990-07-13 | 1992-04-20 | Konica Corp | Photographic coupler |
FR2677356B1 (en) * | 1991-06-05 | 1995-03-17 | Sanofi Sa | HETEROCYCLIC DERIVATIVES OF SUBSTITUTED ACYLAMINO-2 THIAZOLES-5, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. |
JPH07128824A (en) | 1993-11-05 | 1995-05-19 | Konica Corp | Photographic coupler |
US5530000A (en) * | 1993-12-22 | 1996-06-25 | Ortho Pharmaceutical Corporation | Substituted pyrimidinylaminothiazole derivatives useful as platelet aggreggation inhibitors |
JPH10504542A (en) * | 1994-07-27 | 1998-05-06 | ジー.ディー.サール アンド カンパニー | Substituted thiazole compounds for treating inflammation |
US5854265A (en) * | 1996-04-03 | 1998-12-29 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
US5874452A (en) * | 1996-04-03 | 1999-02-23 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
US6063930A (en) | 1996-04-03 | 2000-05-16 | Merck & Co., Inc. | Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
US5872136A (en) * | 1996-04-03 | 1999-02-16 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
US6080870A (en) | 1996-04-03 | 2000-06-27 | Merck & Co., Inc. | Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
US5939557A (en) * | 1996-04-03 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5880140A (en) * | 1996-04-03 | 1999-03-09 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
US5883105A (en) * | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5859035A (en) * | 1996-04-03 | 1999-01-12 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
US6069162A (en) | 1996-05-27 | 2000-05-30 | Fujisawa Pharmaceutical Co., Ltd. | Indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production |
DE69821132T2 (en) | 1997-10-27 | 2004-10-21 | Takeda Chemical Industries Ltd | 1,3-THIAZOLE AS ADENOSINE A3 RECEPTOR ANTAGONISTS FOR TREATING ASTHMA, ALLERGIES AND DIABETES |
WO1999064418A1 (en) | 1998-06-05 | 1999-12-16 | Novartis Ag | Aryl pyridinyl thiazoles |
AU2164300A (en) | 1998-12-04 | 2000-06-26 | N.V. Organon | Substituted thiazoles for treatment of human diseases involving modulators of p-, l- and e- selectin |
JP2000302680A (en) | 1999-04-23 | 2000-10-31 | Takeda Chem Ind Ltd | Brain protective agent |
AU4315100A (en) | 1999-04-28 | 2000-11-17 | Sankyo Company Limited | Preventive or inhibitory agents for hepatopathy |
AU2001239754A1 (en) | 2000-02-25 | 2001-09-03 | Avon Products Inc. | Topical compositions containing thiazolium compounds and methods of using same |
US7105550B2 (en) | 2000-03-01 | 2006-09-12 | Christopher Love | 2,4-disubstituted thiazolyl derivatives |
-
2000
- 2000-11-21 GB GBGB0028383.8A patent/GB0028383D0/en not_active Ceased
-
2001
- 2001-11-19 AR ARP010105397A patent/AR035371A1/en unknown
- 2001-11-19 BR BR0115478-8A patent/BR0115478A/en not_active Application Discontinuation
- 2001-11-19 JP JP2002544432A patent/JP3973556B2/en not_active Expired - Fee Related
- 2001-11-19 AU AU2002237221A patent/AU2002237221A1/en not_active Abandoned
- 2001-11-19 SK SK603-2003A patent/SK6032003A3/en unknown
- 2001-11-19 NZ NZ525875A patent/NZ525875A/en unknown
- 2001-11-19 CN CNB018192882A patent/CN1244580C/en not_active Expired - Fee Related
- 2001-11-19 RU RU2003117476/04A patent/RU2003117476A/en not_active Application Discontinuation
- 2001-11-19 IL IL15571201A patent/IL155712A0/en unknown
- 2001-11-19 AT AT01986395T patent/ATE300536T1/en not_active IP Right Cessation
- 2001-11-19 US US10/432,302 patent/US7109202B2/en not_active Expired - Fee Related
- 2001-11-19 WO PCT/EP2001/013378 patent/WO2002042298A1/en active IP Right Grant
- 2001-11-19 HU HU0302079A patent/HUP0302079A2/en unknown
- 2001-11-19 MX MXPA03004439A patent/MXPA03004439A/en unknown
- 2001-11-19 DE DE60112322T patent/DE60112322T2/en not_active Expired - Lifetime
- 2001-11-19 EP EP01986395A patent/EP1339711B1/en not_active Expired - Lifetime
- 2001-11-19 ES ES01986395T patent/ES2246346T3/en not_active Expired - Lifetime
- 2001-11-19 KR KR10-2003-7006156A patent/KR20040007412A/en not_active Application Discontinuation
- 2001-11-19 CA CA002429442A patent/CA2429442A1/en not_active Abandoned
- 2001-11-19 PL PL01361842A patent/PL361842A1/en not_active Application Discontinuation
- 2001-11-19 CZ CZ20031393A patent/CZ20031393A3/en unknown
- 2001-11-20 PE PE2001001159A patent/PE20020580A1/en not_active Application Discontinuation
-
2003
- 2003-05-14 ZA ZA200303721A patent/ZA200303721B/en unknown
- 2003-05-16 EC EC2003004611A patent/ECSP034611A/en unknown
- 2003-05-20 NO NO20032277A patent/NO20032277L/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2004521871A5 (en) | ||
ES2242351T3 (en) | IMIDAZOL SUBSTITUTED DERIVATIVES AND ITS USE AS CYTOKIN INHIBITORS. | |
RU2270194C2 (en) | BENZOPHENONES AS INHIBITORS OF IL-β AND TNF-α, PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD | |
RU2491286C1 (en) | Polymorphous form of 2-aminothiazole compounds as kinase inhibitor and method of its obtaining | |
JP6158811B2 (en) | Crystalline polymorph of 4- [5- (pyridin-4-yl) -1H-1,2,4-triazol-3-yl] pyridine-2-carbonitrile and process for producing the same | |
EP2650287B9 (en) | Thiazole Derivative and use thereof as VAP-1 Inhibitor | |
JP2004509113A5 (en) | ||
JP2007529479A (en) | Use of indazole carboxamide derivatives for the preparation of a medicament intended for the treatment and prevention of malaria | |
CZ2001934A3 (en) | Arylsulfonanilide ureas | |
WO1992009279A1 (en) | 2-arylthiazole derivative and pharmaceutical composition containing the same | |
JPH04503212A (en) | 4-Hydroxythiazole as a 5-lipoxygenase inhibitor | |
CZ228892A3 (en) | Thiourea derivative and pharmaceutical preparation comprising thereof | |
JP2010510976A (en) | Novel process for the preparation of 2-imino-thiazolidin-4-one derivatives | |
KR20000052738A (en) | 1-Phenylpyrazole Compounds and Pharmaceutical Use Thereof | |
JPH0460990B2 (en) | ||
CZ280803B6 (en) | Derivative of 2-aminothiazole or 2-aminooxazole and 5-amino-1,2,4-oxadiazole or 5-amino-1,2,4-oxathiazole, process of its preparation and pharmaceutical preparation containing thereof | |
JPH0390062A (en) | Substituted n-(quinoline-2-yl-methoxy) benzylsulfonyl urea | |
JPH04300874A (en) | New 2,4-diamino-1,3,5-triazine derivative | |
JPH04300832A (en) | Leukotriene antagonistic agent containing 2,4-diamino-1,3,5-triazine derivative as active ingredient | |
JP2003012667A (en) | Antimicrobial agent having quinolin carboxamide skelton | |
JP2008545690A (en) | New compounds | |
US20200392099A1 (en) | Agents and methods for treating dysproliferative diseases | |
US4859679A (en) | Antiulcer (alkyldithio) quinoline derivatives | |
US4055650A (en) | Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines | |
JP2005041802A (en) | Method for producing 1,2,4-triazole compound |